Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2026-04-23 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
2025年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告及财务报表" (Audit Report and Financial Statements) for the fiscal year 2025, covering the period from January 1, 2025 to December 31, 2025. It includes detailed audit opinions, key audit matters, and comprehensive financial statements such as consolidated and parent company balance sheets, profit and loss statements, and cash flow statements. The presence of an independent auditor's opinion, detailed audit procedures, and extensive financial data confirms this is a standalone audit report rather than a full annual report or a brief announcement. The document length (15,000 characters) and content depth further support this classification. Therefore, the document fits the category of Audit Report / Information (AR). FY 2025
2026-04-23 Chinese
2025年年度报告
Annual Report Classification · 100% confidence The document is titled "2025 年年度报告全文" which translates to "2025 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data, management discussion and analysis, governance, risk factors, and detailed financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial data, management's discussion, and detailed business descriptions. The presence of signatures from company officers and auditors further confirms this is the full annual report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-04-23 Chinese
对外担保管理制度（2026年4月修订)
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '对外担保管理制度' (External Guarantee Management System) for a company, outlining rules, procedures, responsibilities, and governance related to external guarantees provided by the company. It references relevant laws and regulations, internal approval processes, disclosure obligations, and risk management. There is no indication that this is a financial report, audit, earnings release, or any form of shareholder meeting material. It is a governance-related document detailing internal rules and procedures for managing external guarantees. Therefore, it fits best under Governance Information (CGR). The document length is 4448 characters, which is sufficient for a substantive policy document rather than a brief announcement or certification.
2026-04-23 Chinese
关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (立信会计师事务所) as the auditor for the company 亿帆医药股份有限公司 for the fiscal year 2026. It details the auditor's qualifications, past performance, audit fees, and the approval process by the audit committee and board of directors. There is no actual audit report or financial statements included, only information about the auditor's reappointment and related procedural details. The document is about the appointment of the audit firm for the upcoming audit, not the audit report itself. Therefore, it is best classified as an Audit Report / Information (AR) type, which includes standalone audit-related announcements and information about audit firms and their engagement, but not the full annual report or audit report itself. The document length is 6008 characters, which is sufficient for a detailed announcement but does not contain the full audit report. Hence, the classification is AR with high confidence. FY 2026
2026-04-23 Chinese
独立董事述职报告 （刘洪泉已离任）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 by an independent director of the company. It details the director's duties, attendance at board and shareholder meetings, committee participation, communication with auditors, and oversight activities during the year. The content focuses on the director's role and activities rather than financial results or audit opinions. It is a formal report on the independent director's performance and compliance with regulations, which fits the category of Board/Management Information (MANG) as it relates to governance and management oversight rather than a full annual report or audit report. The document length is 4331 characters, which is substantial and contains detailed narrative rather than a brief announcement or certification. Therefore, the best classification is MANG with high confidence.
2026-04-23 Chinese
关于举行2025年度网上业绩说明会的通知
Investor Presentation Classification · 95% confidence The document is a notice about holding the 2025 annual performance explanation meeting (业绩说明会) for 亿帆医药股份有限公司. It announces the date, time, and participation details for an online earnings presentation event, including the names of attending executives. The document invites investors to submit questions in advance for the meeting. The text does not contain actual financial results or detailed financial statements but rather serves as an announcement for the upcoming earnings call or presentation. Given the nature of the document as a notice for an earnings explanation meeting, it fits best under the category of Investor Presentation (IP). The document length is short and it is not a report itself but an announcement of a meeting where financial results will be discussed, which aligns with the Investor Presentation category rather than an Earnings Release or Interim Report.
2026-04-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.